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esponsibility of InstAbstract MicroRNAs (miRNAs) are a class of phylogenetically conserved, non-coding short RNAs,
19–22 nt in length which suppress protein expression through base-pairing with the 30-untranslated region
of target mRNAs. miRNAs have been found to participate in cell proliferation, differentiation and
apoptosis. Idiopathic pulmonary ﬁbrosis (IPF) is a chronic, progressive, and high lethality ﬁbrotic lung
disease for which currently there is no effective treatment. Some miRNAs have been reported to be
involved in the pathogenesis of pulmonary ﬁbrosis. In this review, we discuss the role of miRNAs in the
pathogenesis, diagnosis and treatment of IPF.
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Huimin Li et al.5321. Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is an interstitial lung disease
with unknown cause and unclear pathogenesis. Of the idiopathic
interstitial pneumonia family of diseases, it is the most common
and has the highest morbidity and worst prognosis. Currently,
there is no effective treatment for IPF1.
The formation of ﬁbroblastic foci and the excessive deposition
of extracellular matrix (ECM) are regarded as factors that directly
induce IPF2. Myoﬁbroblasts, which have the features of both
ﬁbroblasts and smooth muscle cells, overexpress α-smooth muscle
actin (α-SMA) and extensively synthesize and secrete ECM.
Finally, they lead to the remodeling of lung tissue observed in
IPF patients3–5. Previous research has shown that myoﬁbroblasts
in the lung arise mainly from ﬁbroblasts and epithelial cells and, to
a lesser extent, from circulating ﬁbroblasts derived from bone
marrow cells. Of these, ﬁbroblasts and epithelial cells are
considered to be the main sources of myoﬁbroblasts6–8.
MicroRNAs (miRNAs) are a class of non-coding single-
stranded RNAs, 19–22 nt in length, which can complementary
base-pair to the 3ʹ-untranslated region (UTR) of targets and repress
the translation of target genes or degradation of target mRNAs9.
Recently, as the result of an in-depth study of miRNAs, we found
that deregulation of miRNAs participates in the progression ofTable 1 Role of microRNAs in idiopathic pulmonary ﬁbrosis.
Putative role No. miRNA Target
Pro-ﬁbrotic 1 miR-21 Smad7
2 miR-199a-5p CAV-1
3 miR-145 KLF4
4 miR-154 CDKN2B
5 miR-155 KGF
6 miR-96 FoxO3
7 miR-142-5p SOCS1
8 miR-210 MNT
Anti-ﬁbrotic 9 Let-7d HMGA2
10 miR-26a CTGF/Smad4/CCND2
HMGA2
11 miR-375 Frizzled 8
12 miR-200
13 miR-1343 TGFBR1/TGFBR2
14 miR-31 RhoA, Integrin α5
15 miR-27a-3p α-SMA, Smad2, Smad4
16 miR-27b Gremin1
17 miR-92a WISP1
18 miR-486-5p Smad2
19 miR-9-5p TGFBR2, Nox4
20 miR-153 TGFBR2
21 miR-29 ITGA11, ADAMTS9,
ADAM12, NID1
22 miR-1792 DNMT1
23 miR-130a-3p PPARγ
24 miR-326 TGF-β1
NHLF, normal human lung ﬁbroblast; FLF, human fetal lung ﬁbroblast; Hﬁbrosis in different tissues including liver, kidney and myocar-
dium. Here, we review the key roles played by miRNAs in the
pathogenesis of IPF and their signiﬁcance in its diagnosis and
treatment (Fig. 1 and Table 110–40).2. The role of miRNAs in alveolar epithelial cells of IPF
Normal epithelial cells are closely linked to each other through the
intercellular adhesion mechanism. E-cadherin is a key component
in the tight junctions of epithelial cells where it maintains their
integrity and polarity. The ability of epithelial cells to change into
mesenchymal cells through the epithelial–mesenchymal transition
(EMT) plays an important role in the development of IPF. As a result
of the EMT, alveolar epithelial cells (AECs) lose their intrinsic
polarity and intercellular adhesion and gain the ability to migrate.
AECs produce a large amount of ECM which eventually leads to the
development of ﬁbrosis7. Current studies conﬁrm that many
miRNAs including let-7d, miR-200, miR-26a and miR-375 partici-
pate in IPF through regulating EMT19,23–26,29,40–42. They also have
reduced expression in IPF patients whereas the expression of their
target gene, high-mobility group A protein 2 (HMGA2), is obviously
up-regulated. This leads to a change in epithelial cell phenotype, the
deposition of collagen and development of IPF.Tissue/Cell type Ref.
Mice/MRC-5 10,11
Mice/MRC-5 12
Mice/MRC-5 13
NHLF 14
NHLF 15
NHLF 16
Mice/ Macrophages 17
NHLF 18
IPF ﬁbroblasts
Mice/A549,FLF, NHLF, HFF-1 19,20
Mice/MRC-5 21
NHLF 22
Mice/A549 23
Rat/AEC II 24
Mice/ 25
AEC, RLE-6TN
A549 26
Mice/MRC-5 27
IPF ﬁbroblasts
IPF ﬁbroblasts 28
A549 29
Mice/ NHLF 30
Mice/NIH/3T3 31
Mice/ NHLF 32
MRC-5 33
Mice 34,35
Mice/IMR-90 36
IMR-90 37
IPF ﬁbroblasts 38
NHLF 39
IPF ﬁbroblasts
Mice/Macrophages 17
Mice/A549, NIH/3T3 40
FF-1, human fetal foreskin ﬁbroblasts.
Figure 1 The alteration of miRNAs and their role in the progression of IPF.
MicroRNAs in idiopathic pulmonary ﬁbrosis 533Let-7 was originally discovered in Caenorhabditis elegans where
its role is to regulate cell differentiation and proliferation, a role
conserved in different species. The human let-7 family includes 12
members (let-7-al, -a2, -a3, -b, -c, -d, -e, -ﬂ, -f2, -g, -i and miR-98),
located on 8 different homologous chromosomes43. Through
miRNA microarray analysis of lung tissue from healthy controls
and IPF patients, Pandit et al.19 found that levels of 18 miRNAs
including let-7d were reduced in IPF patients. They also found that
the expression of let-7d was decreased and the expression of
HMGA2 was increased in A549 AECs stimulated by TGF-β1. This
was subsequently shown by electrophoretic mobility shift assays,
chromatin immunoprecipitation and luciferase assays, resulting from
binding between Smad3 and the let-7d promoter. In addition, speciﬁc
inhibition of let-7d in mouse lung tissue was shown to induce the
EMT thereby increasing the thickness of the alveolar walls and
eventually causing pulmonary ﬁbrosis.
It has been reported that miR-26a plays an important role in the
regulation of many diseases. Harada et al.44 conﬁrmed that miR-26a
can inhibit cardiac ﬁbroblast proliferation and differentiation by
down-regulating the expression of TRPC3 and thereby control
atrial ﬁbrillation. Wei et al.45 showed that miR-26a decreased the
expression of collagen I which is induced by angiotensin II (Ang-II)
and up-regulated the expression of connective tissue growth factor
(CTGF). All these results indicate that miR-26a has the ability to
prevent ﬁbrosis.
In our study, differential expression and cluster analysis using a
bioinformatics method showed that genes participating in EMT
were differentially expressed in lung tissue of IPF patients, a result
validated by immunoﬂuorescence in pulmonary ﬁbrotic mice.
Moreover, we conﬁrmed that miR-26a regulated EMT by binding
to the HMGA2 gene and inhibiting its expression. Moreover,
forced expression of miR-26a inhibited the occurrence of EMT
and the expression of EMT-related genes. Taken together, our
study conﬁrms that miR-26a inhibits EMT and thereby reduces the
occurrence of IPF23.
The TGF-β and Wnt pathways are the most well-known
pathways involved in lung ﬁbrosis. Besides participating in theproliferation and differentiation of ﬁbroblasts, they also promote
EMT. A recent study by Das et al.40 showed that miR-326 was
reduced in lung ﬁbrosis causing induction of TGF-β1. In contrast,
enhanced expression of miR-326 dampens lung ﬁbrosis by post-
transcriptional regulation of TGF-β1. Alternatively, Stolzenburg et al.26
found that miR-1343 attenuates EMT and ﬁbrogenesis by directly
targeting TGF-β receptors 1 and 2. In another study, Wang et al.24
found that miR-375 was decreased during trans-differentiation of
AECs and that ectopic expression of miR-375 inhibited EMT by
direct binding to the 3ʹ-UTR of Frizzled 8 and thereby blocked the
Wnt/β-catenin pathway.
Previous studies have shown that the expression of the miR-30
family (miR-30a, miR-30c, miR-30d and miR-30e) is down-
regulated in patients with IPF19. miR-30c and miR-30e are located
in the intron of nuclear transcription factor Y subunit γ (NFYC)
and can inhibit the expression of Smad3. In the lung tissue of IPF
patients, the level of NFYC mRNA is signiﬁcantly reduced.
Studies found that miR-30 was located in AECs and that down-
regulation of miR-30 increased the expression of endothelin
receptor A and HMGA2 leading to EMT and the deposition of
collagen41. In addition, the miR-200 family, whose over-
expression can inhibit the EMT, was down-regulated in IPF
patients. Injection of miR-200 to mice clearly enables them to
resist pulmonary ﬁbrosis25.3. The role of miRNAs in ﬁbroblasts of IPF
Proliferation of ﬁbroblasts and their differentiation into myoﬁbro-
blasts are important in the development of IPF. Several studies
have shown that some miRNAs including miR-21, miR-155, miR-26a,
miR-27a-3p and miR-9-5p can regulate the function of ﬁbroblasts
in lung12–16,18,20,21,27,28,30–33,41,46.
The miR-21 host gene in human is located on chromosome
17p23 and has independent promoters for transcription. miR-21 is
widely expressed in tissues and is not essential for normal tissue
development as veriﬁed by knockout of miR-21 in mice47. Liu
Huimin Li et al.534et al.10 found that miR-21 is up-regulated in IPF patients and only
a small amount of miR-21 is expressed in normal lung tissue of
mice. However, after stimulating with bleomycin, the expression
of miR-21 was clearly up-regulated which promoted the accumu-
lation of myoﬁbroblasts. The research showed that even at 5–7
days after the lung injury, the expression of miR-21 could be
inhibited by an miR-21 antisense probe sufﬁciently to reduce or
eliminate IPF. TGF-β1 is the most important pro-ﬁbrogenic
cytokine which increases the expression of miR-21 in lung
ﬁbroblasts. Further studies showed that Smad7 is a direct target
gene of miR-21. Thus, miR-21 causes the activation of the TGF-β1
pathway and ultimately promotes the occurrence and development
of IPF by targeting Smad7. Taken together, TGF-β1 promotes IPF
by regulating an miR-21/Smad7 feedback loop11,48.
Our research has revealed that the expression of miR-26a is
signiﬁcantly reduced in lung tissues of mice and patients with IPF
accompanied by activation of the TGF-β1 pathway and increased
expression of the miR-26a target protein CTGF. Inhibition of miR-26a
promotes collagen deposition in the lungs of mice. In contrast, over-
expression of miR-26a inhibits experimental pulmonary ﬁbrosis in
mice. Further studies conﬁrmed that miR-26 inhibits lung ﬁbrosis
through its ability to regulate the expression of CTGF and thereby
inhibit the differentiation and proliferation of ﬁbroblasts.
We also found that Smad3, a downstream gene of TGF-β1,
inhibits the expression of miR-26a and that miR-26a affects the
nuclear translocation of Smad3 by regulating Smad4. The TGF-β1
pathway is activated by external stimulation to phosphorylate
Smad3 which translocates into the nucleus and inhibits the
expression of miR-26a. Subsequently post-transcriptional expres-
sion of CTGF promotes the differentiation and proliferation of
ﬁbroblasts in lung and further increases the collagen content. In
addition, down-regulation of miR-26a increases the expression of
Smad4 and promotes the translocation of Smad3 to the nucleus to
inhibit the expression of miR-26a. This loop repeats and aggravates
pulmonary ﬁbrosis. Furthermore, treatment with exogenous miR-26a
leads to inhibition of Smad3 translocation such that Smad3
inhibition of miR-26a vanishes, further strengthening the thera-
peutic effect of miR-26a. The above results indicate that miR-26a
inhibits the proliferation and differentiation of ﬁbroblasts by
targeting CTGF and then reduces collagen secretion to ultimately
reduce pulmonary ﬁbrosis. Further evidence of the potential of
miR-26a to prevent and treat pulmonary ﬁbrosis21 comes from Li
et al.22 who conﬁrmed that it regulates cyclin D2 (CCND2) and
inhibits the proliferation of ﬁbroblasts induced by activation of
TGF-β1.
The miR-155 gene located on chromosome 21p21 generates
miR-155 in hematopoietic cells to play an important role in
inﬂammatory and immunological reactions49. Marshall et al.50
found that it participates in pulmonary ﬁbrosis by targeting the
Ang-II type 1 receptor (AT1R) which is located in stromal
ﬁbroblasts and has increased expression in lungs of IPF patients
and in mice treated with bleomycin. This increased expression
enhances collagen synthesis in ﬁbroblasts and promotes the
development of pulmonary ﬁbrosis. Furthermore, Pottier et al.15
showed that miR-155 is up-regulated in ﬁbrotic mice. Functional
studies have demonstrated that the keratinocyte growth factor gene
(KGF) is a direct target of miR-155, up-regulation of which
inhibits KGF expression. After transfection of miR-155, the
migration ability of ﬁbroblasts was signiﬁcantly increased15.
miR-31 is a negative regulator of pulmonary ﬁbrosis. It is found
that miR-31 expression is reduced in the lungs of mice with
experimental pulmonary ﬁbrosis and in IPF ﬁbroblasts. Over-expression of miR-31 inhibits ﬁbrogenic, contractile and migratory
activities of ﬁbroblasts in vivo to alleviate bleomycin-induced
pulmonary ﬁbrosis27.
An increasing number of studies51–53 have shown that the
generation of reactive oxygen species (ROS) contributes to the
pathogenesis of ﬁbrotic diseases including IPF. A recent study
showed that hydrogen peroxide (H2O2) cause the dysregulation of
many miRNAs in human fetal lung ﬁbroblasts (HFL-1)32. Among
them, miR-9-5p was identiﬁed as being anti-ﬁbrotic because of its
reduced response to H2O2, and because many genes involved in
the TGF-β pathway are its predicted targets. Another study showed
that miR-9-5p was down-regulated in a mouse model of lung
ﬁbrosis and in IPF patients. Moreover, forced expression of miR-9-5p
attenuated the TGF-β1-induced ﬁbrogenic pathway in HFL and
prevented experimental lung ﬁbrosis in mice by regulating
expression of TGF-β receptor type II (TGFBR2) and NADPH
oxidase 4 (NOX4)32.4. miRNAs inhibit collagen deposition and regulate the
synthesis of ECM in IPF
IPF is induced by the necrosis of parenchymal cells that result
from inﬂammation and deposition of ECM. If the synthesis of
ECM and collagen deposition are inhibited, the development of
IPF can be greatly weakened or even eliminated. Current studies
conﬁrm that miRNAs can participate in pulmonary ﬁbrosis by
directly regulating the generation of collagen34,36,41,54–56.
Cushing et al.51 found that the expression of miR-29 was
signiﬁcantly reduced in mice with bleomycin-induced pulmonary
ﬁbrosis and down-regulated in human embryonic lung ﬁbroblasts
(IMR-90) stimulated by TGF-β1. This suggests that miR-29 may
be involved in pulmonary ﬁbrosis. A further study showed that
down-regulation of miR-29 was negatively related to the up-
regulation of genes, promoting ﬁbrosis such as the collagen genes
in ECM and basement membrane57. In fact many genes which
regulate ECM, such as ELN, FBN1, COL1A1, COL1A2 and
COL3A1, are target genes of miR-2957. In addition, miR-29
inhibits TGF-β1-induced ECM synthesis in human lung ﬁbroblasts
through activating the PI3K/AKT pathway37. Furthermore, studies
have shown34,35,55 that over-expression of miR-29 can inhibit
bleomycin-induced pulmonary ﬁbrosis in mice. More importantly,
a recent study by Khalil et al.38 showed that interaction of IPF
ﬁbroblasts with collagen 1 resulted in decreased protein phospha-
tase (PP) 2A and histone deacetylase (HDA) C4 phosphorylation
leading to decreased nuclear translocation of HDAC4 and ﬁnally
reduction of miR-29 and a pathological increase in type I collagen
expression.
The TargetScan database (http://www.targetscan.org/) predicts
that Col1a2 (Collagen, type 1, α2) is a potential target of miR-26a.
Wei et al.45 conﬁrmed that miR-26a directly regulates Col1a2 and
inhibits cardiac ﬁbrosis. The issues of whether Col1a2 also
mediates the anti-ﬁbrotic effects of miR-26a and whether there
are other miRNAs directly regulating collagen synthesis in
pulmonary ﬁbrosis warrant further research.5. miRNAs participate in pulmonary ﬁbrosis through other
mechanisms
miRNAs participate in IPF by multiple mechanisms. Methylation,
including DNA methylation and histone methylation, is one of the
MicroRNAs in idiopathic pulmonary ﬁbrosis 535important ways that genes are regulated which is closely related to
embryonic development, aging, cancer and many other physiolo-
gical and pathological processes58–60. Some recent studies suggest
that deregulation of methylation may be involved in the
ﬁbrotic process61–63. For example, in IPF patients, 80% of the
miR-1792 cluster promoter was found to be occupied by areas
of cytosine polyguanine (CPG) and was signiﬁcantly hyper-
methylated compared with normal lung tissue. A further study
showed that introduction of miR-1792 into lung ﬁbroblasts of
IPF patients reduced the expression of many ﬁbrotic genes such as
CTGF, COL1A1 and COL13A1 by direct regulation of DNA
methyltransferase-1 (DNMT-1)39.
On this basis, we hypothesize that miRNAs are involved in IPF
through complex pathways. For instance, miRNAs can participate
in pulmonary ﬁbrosis by regulating early inﬂammation of lung
damage indicating they may be therapeutic targets in IPF17,64.
Zhang et al.64 found that miR-199a-5p was increased in cystic
ﬁbrosis (CF) macrophages and lung tissue which induced a hyper-
inﬂammatory response in CF MΦs through targeting caveolin-1
(CAV1) to activate toll-like receptor 4 (TLR4) signaling. Further-
more, inhibition of miR-199a-5p restored CAV1 expression and
alleviated the hyper-inﬂammation in CF MΦs. In addition, Su
et al.17 conﬁrmed that miR-142-5p and miR-130a-3p regulate
macrophage ﬁbrogenesis in liver ﬁbrosis and lung ﬁbrosis. They
found that the up-regulation of miR-142-5p and down-regulation
of miR-130a-3p in macrophages in response to interleukin (IL)-3
in tissue samples from patients with liver cirrhosis and IPF by
direct regulation of their targets, the suppressor of cytokine
signaling 1 (SOCS1) and peroxisome proliferator-activated recep-
tor γ (PPARγ), respectively. More importantly, inhibition of
miR-142-5p or over-expression of miR-130a-3p attenuated liver
ﬁbrosis and lung ﬁbrosis in mice.6. Deregulated miRNA network in IPF
It is known that one miRNA can regulate several target genes and
one gene can be regulated by several miRNAs at the same time. In
addition, many ﬁbrosis related genes such as TGF-β1 and HIF-1
can act as transcription factors to regulate the expression of
miRNAs. Thus, miRNAs and their targets form a complex
network in the process of IPF.
Smad3, a transcription factor, can regulate the expression of
many miRNAs including let-7d and miR-154. Using electrophore-
tic mobility shift assays, chromatin immunoprecipitation and
luciferase assays, Pandit et al.19 conﬁrmed that TGF-β1 inhibits
the expression of let-7d by promoting Smad3 to bind with its
promoter. Milosevic et al.14 found that Smad3 binds to the 322 bp
site of the miR-154 precursor and regulates its expression. Our
group found that p-Smad3 inﬂuenced the down-regulation of miR-26a
and that, moreover, miR-26a inhibited the nuclear transcription of
p-Smad3 by regulating Smad421. One can speculate that miR-26a
affects the generation of other miRNAs by regulating Smad3 and
that miRNAs interact with each other and exert synergistic roles in
pulmonary ﬁbrosis.
Some studies have shown that miRNAs can regulate the
generation of other miRNAs. Chen et al.65 found that miR-107,
by binding to the let-7 sequence, inhibited the expression of let-7
and induced the initiation and metastasis of breast cancer. Guo
et al.66 constructed an miRNA–miRNA interaction network
involving a mutual regulatory pattern in different species. In
recent work in our laboratory, we showed that miR-26a increasedthe expression of let-7d by regulating Lin28B suggesting that
miR-26a and let-7d act synergistically to ameliorate pulmonary
ﬁbrosis42. Furthermore, miR-26a reduces the expression of miR-21
possibly through the mediation of Smad3 or another transcription
factor. Based on these results, we constructed an miRNAs-
transcription factor (TF)-miRNAs regulation network in IPF which
warrants further validation through future experiments.
We also analyzed the miRNA expression proﬁle in IPF using
the microarray dataset (GSE32538)67. Surprisingly, we found that
more than 80% of miRNAs were down-regulated in IPF patients.
This is consistent with the results of previous studies showing
miRNAs are decreased in the lungs of mice with experimental
pulmonary ﬁbrosis and in IPF and that they all exert potential anti-
ﬁbrotic effects in the progression of IPF (Table 1). Thus, further
studies are needed to investigate what causes the global down-
regulation of miRNAs in IPF.7. miRNAs act as biomarkers for early diagnosis of IPF
miRNAs that are differentially expressed in respiratory
diseases may be biomarkers for their diagnosis, molecular
classiﬁcation and prognosis. The existing literature indicates that
(1) miR-21 and miR-126 are up-regulated and miR-672
and miR-143 are down-regulated in an asthmatic rat model68
and (2) miR-155, miR-21, miR-17-92 and miR-221/222 are up-
regulated and let-7, miR-1, miR-29 and miR-126 down-regulated
in lung cancer69. In fact, studies70,71 have shown that different
sub-types of lung cancer or non-cancer diseases can be distin-
guished by their miRNA expression proﬁles. For example,
Chen et al.70 reported that eight miRNAs are differentially
expressed in the serum of lung cancer patients compared with
normal lung tissues.
Lam et al.71 showed that the expression of miR-26a was
signiﬁcantly decreased in rats with experimental silicosis and
patients with lung cancer. Furthermore, miR-26a was signiﬁcantly
down-regulated in lung tissues and sputum of rats exposed to
cigarette smoke72,73. van Pottelberge et al.72 reported that miR-26a
was clearly down-regulated in the plasma of patients with chronic
obstructive pulmonary disease (COPD) compared with normal
smokers. However, a study by Ezzie et al.74 found no obvious
differential expression of miR-26a in COPD patients compared to
normal controls. Therefore, there is still debate about the role of
miR-26a in COPD.
Yang et al.75 found 47 differentially expressed miRNAs in the
serum of IPF patients including 21 that were up-regulated and 26
down-regulated. The results of quantitative RT-PCR conﬁrmed
that expression of miR-21, miR-199a-5p, and miR-200c was
signiﬁcantly increased in serum of IPF patients while the opposite
was true for miR-31, let-7a and let-7d. These results suggest that
miRNAs may be useful diagnostic markers for the diagnosis,
prognosis and treatment of IPF76.8. miRNAs as therapeutic targets in IPF
The fact that abnormal expression or mutation of miRNAs leads to
disease suggests speciﬁc miRNAs can be used as potential targets
for their treatment and control. Theoretically, the expression of
down-regulated miRNAs in IPF can be restored by importing an
adenovirus vector that contains the target miRNA. Conversely, up-
regulated miRNAs can be down-regulated using an antisense
oligonucleotide such as 20-O-methyl, 20-O-methoxy ethyl and
Huimin Li et al.536locked nucleic acid (LNA) antisense oligonucleotides to directly
bind to miRNAs and block their activity77.
Lanford et al.78 found that treatment of chronically infected
chimpanzees with an LNA-modiﬁed oligonucleotide (SPC3649)
complementary to miR-122 suppressed hepatitis C virus (HCV)
viremia with no evidence of viral resistance or side effects. Phase I
research on SPC3649 has now been completed and a phase IIA
clinical trial begun. SPC3649 may be the ﬁrst drug that targets
miRNAs to be used in the treatment of a human disease.
In a mouse model of myocardial hypertrophy, inhibiting miR-
21 with an antagonist was found to decrease the activity of ERK/
MAPK, block the myocardial interstitial ﬁbrosis and reduce
myocardial dysfunction79. Similarly, in renal ﬁbrotic mice, inhibit-
ing the expression of miR-21 reduced renal damage80. Meng et
al.81 were the ﬁrst to report that chemotherapeutic drugs can affect
miRNA expression in human cancer cells. They found that treating
tumor cell xenografts with systemic gemcitabine altered the
expression of miRNAs. They also found that miR-21 was up-
regulated in bile duct cancer cells which increased their sensitivity
to chemotherapeutic drugs81. Kota et al.82 successfully delivered
miR-26a to mice with liver cancer using an adeno-associated virus
(AAV) and found that AVV did not integrate into the human
genome although it was clearly present in liver cells. These
ﬁndings may provide new hope for the treatment of liver cancer.
Although extensive research has revealed the mechanisms of
miRNAs in IPF and shown their therapeutic potential, clinical
application of miRNAs is confronted with many problems. One is
the lack of targeted miRNA delivery technology to solve off-target
effects and improve the safety of miRNAs in vivo.9. Long non-coding RNAs (lncRNAs) in pulmonary ﬁbrosis
Long non-coding RNAs (lncRNAs) are a class of non-coding
RNAs with more than 200 nucleotides (nt) without protein-coding
function83. There is a great deal of evidence showing that they
play a major role in various diseases, including cancer, cardiovas-
cular disease and lung disorders84,85. Recently, lncRNAs have
been recognized as pivotal mediators in the initiation and main-
tenance of various cancers and heart diseases by competitive
binding miRNAs86–88. However, the role and mechanisms of
lncRNAs in pulmonary ﬁbrosis remains largely elusive.
Cao and colleagues89 ﬁrstly identiﬁed the differential expres-
sion proﬁle of lncRNAs in bleomycin-induced lung ﬁbrosis in
mice. Of the many lncRNAs, 210 were up-regulated and 358
down-regulated. In this study, they also validated two up-regulated
lncRNAs, AJ005396 and S69206, in ﬁbrotic lung tissue by in-situ
hybridization89, In addition, Sun et al.90 identiﬁed the differential
expression of lncRNAs in paraquat-driven experimental lung
ﬁbrosis in mice, and also found that forced expression of the
lncRNAs, uc.77 and 2700086A05Rik, caused EMT by regulation
of Zeb2 and Hoxa3 and contributed to lung ﬁbrosis.
Song et al.91 identiﬁed two other up-regulated lncRNAs,
MRAK088388 and MRAK081523, in lung ﬁbrosis and found
that MRAK088388 regulates N4bp2 by sponging miR-29b-3p
whereas MRAK081523 regulates Plxna4 by binding to let-7i-5p.
This indicates that MRAK088388 and MRAK081523 display
regulatory functions as competing endogenous RNAs (ceRNAs)
and contribute to pulmonary ﬁbrosis. In addition, a recent study by
Huang et al.92 found 34 lncRNAs containing potential binding
sites for several well-known lung ﬁbrosis-related miRNAs includ-
ing miR-21, miR-31, miR-101, miR-29, miR-199 and let-7d. Theythen tested and conﬁrmed four lncRNAs which were inversely
correlated to the miRNA expression in IPF. Further study revealed
that silencing the lncRNA CD99 molecule pseudogene 1
(CD99P1) inhibited ﬁbrogenesis in lung ﬁbroblasts whereas
knockdown of lncRNA n341773 promoted it92.
At the present time, detailed insight into the regulation and
biological roles of lncRNAs in lung ﬁbrosis is just beginning to
emerge. A more detailed and integrated understanding of their
action and mechanisms in pulmonary ﬁbrosis could help pave the
way for effective treatment options for ﬁbrotic-related lung
disease.10. Conclusions and perspectives
Targeting speciﬁc miRNA has great potential in the treatment of
pulmonary ﬁbrosis. In theory, molecular target therapy has highly
speciﬁc effects on target cells and can efﬁciently reduce damage to
normal tissue. However, there are many problems to solve before
miRNA pharmacotherapy of IPF can be introduced. These include:
(1) How do we accurately conﬁrm the target miRNA and its target
gene experimentally and in clinical practice and accurately control
the targeting of miRNAs; (2) Are the in vivo metabolic pathways
of nucleic acid drugs clearly known on the basis of the relevant
pharmacokinetic knowledge; (3) Is it feasible to interfere with
miRNAs in the human body and will such interference bring
unexpected adverse reactions; (4) How are miRNAs or antisense
nucleotide inhibitors introduced into target cells safely and
effectively; and (5) If we develop effective treatments based on
interfering with miRNAs, will the cost be too high.
Although treatment of IPF with miRNAs may have defects,
miRNAs probably represent the most exciting intervention target
of the last ten years. In the future, we have reason to hope
miRNAs or their inhibitors will form the basis of an effective
treatment to alleviate the suffering of IPF patients.
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of the last ten years. In the future, we have reason to hope
miRNAs or their inhibitors will form the basis of an effective
treatment to alleviate the suffering of IPF patients.
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